Research outcomes, once checked, will be made freely available to other scientists, stakeholder organizations, and society at large. To facilitate this, lay person summaries of the research outcomes will be made available in parallel with the publication of peer review papers.

Research in the Alliance will be carried out at the highest levels of excellence because, by collaborating, it is possible for international experts to stay within their domain of competence and work to support the integrated program. Thus, for example, those institutions most competent in characterizing nanomaterials will support the other teams.

In its early phase of development, the alliance intends to focus on the methodologies and procedures by which nanoparticle hazard can be assessed in a reproducible and scientifically sound manner. This is the most urgent priority facing science, industry, regulators, and society at large. This means that efforts will be made to build on current state-of-the-art toxicology and bionanointeraction science, rather than seek entirely new end points.

During this early phase, efforts will also be made to seek correlations between in vitro and in vivo tests. This leaves open the way for future research and testing to reduce reliance on in vivo models. All partners, whilst recognizing the challenges, are committed to striving towards this outcome.

Next phases of research are now being planned to address the need to explore all possible sources of hazard, seeking new end points not classically addressed.